Aclaris Therapeutics (ACRS) Tops Q3 EPS by 7c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.41), $0.07 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $9.28 million versus the consensus estimate of $1.57 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Goldman "broadly" raises estimates for LTL and truckload stocks
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold